Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.

Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J; BIG 1-98 Collaborative Group; International Breast Cancer Study Group.

Br J Cancer. 2012 May 8;106(10):1618-25. doi: 10.1038/bjc.2012.156. Epub 2012 Apr 24.


Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia.

Petit JY, Veronesi U, Orecchia R, Curigliano G, Rey PC, Botteri E, Rotmensz N, Lohsiriwat V, Cassilha Kneubil M, Rietjens M.

Ann Oncol. 2012 Aug;23(8):2053-8. doi: 10.1093/annonc/mdr566. Epub 2012 Jan 9.


Nipple sparing mastectomy: can we predict the factors predisposing to necrosis?

Algaithy ZK, Petit JY, Lohsiriwat V, Maisonneuve P, Rey PC, Baros N, Lai H, Mulas P, Barbalho DM, Veronesi P, Rietjens M.

Eur J Surg Oncol. 2012 Feb;38(2):125-9. doi: 10.1016/j.ejso.2011.10.007. Epub 2011 Nov 6.


Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.


Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group.

Breast Cancer Res. 2011 May 26;13(3):209. doi: 10.1186/bcr2837. Review.


Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.


Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.


Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.


Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.


Long-term oncological results of breast conservative treatment with oncoplastic surgery.

Rietjens M, Urban CA, Rey PC, Mazzarol G, Maisonneuve P, Garusi C, Intra M, Yamaguchi S, Kaur N, De Lorenzi F, Matthes AG, Zurrida S, Petit JY.

Breast. 2007 Aug;16(4):387-95. Epub 2007 Mar 26.


Technical tricks to improve the cosmetic results of breast-conserving treatment.

Petit JY, De Lorenzi F, Rietjens M, Intra M, Martella S, Garusi C, Rey PC, Matthes AG.

Breast. 2007 Feb;16(1):13-6. Epub 2006 Oct 27.


Evaluation of skin perfusion after nipple-sparing mastectomy by indocyanine green dye. Preliminary results.

De Lorenzi F, Yamaguchi S, Petit JY, Rietjens M, Garusi C, Martella S, Rey PC, Gennari R.

J Exp Clin Cancer Res. 2005 Sep;24(3):347-54.


When mastectomy becomes inevitable: the nipple-sparing approach.

Petit JY, Veronesi U, Luini A, Orecchia R, Rey PC, Martella S, Didier F, De Lorenzi F, Rietjens M, Garusi C, Sonzogni A, Galimberti V, Leida E, Lazzari R, Giraldo A.

Breast. 2005 Dec;14(6):527-31. Epub 2005 Oct 12.


Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer.

Kaur N, Petit JY, Rietjens M, Maffini F, Luini A, Gatti G, Rey PC, Urban C, De Lorenzi F.

Ann Surg Oncol. 2005 Jul;12(7):539-45. Epub 2005 May 10.


The "perfusion map" of the unipedicled TRAM flap to reduce postoperative partial necrosis.

Yamaguchi S, De Lorenzi F, Petit JY, Rietjens M, Garusi C, Giraldo A, Rey PC, Urban C, Martella S, Bosco R.

Ann Plast Surg. 2004 Sep;53(3):205-9.


Supplemental Content

Loading ...
Support Center